- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about ESALY
Recent news which mentions ESALY
Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact
March 15, 2022
From Benzinga
From Benzinga
From Benzinga
Merck-Eisai's Keytruda/Lenvima Combo Scores Japanese Approval For Kidney Cancer Setting
February 25, 2022
From Benzinga
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug
January 20, 2022
From Benzinga
Merck Snags Yet Another Indication for This Drug Combo
January 14, 2022
From Motley Fool
From Benzinga
From Benzinga
Europe Approves Merck-Eisai's Keytruda/Lenvima Combo Therapy For Endometrial Carcinoma
November 29, 2021
From Benzinga
Why Are Biogen Shares Gaining Today?
November 12, 2021
From Benzinga
Eisai Posts New Lecanemab Data From Mid-Stage Alzheimer's Trial
November 11, 2021
From Benzinga
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
November 11, 2021
From Benzinga
3 Big Problems With Biogen's Q3 Results
October 23, 2021
From Motley Fool
Eisai, Biogen Initiate Rolling Submission For New Alzheimer's Drug
September 28, 2021
From Benzinga
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
September 28, 2021
From Benzinga
How Keytruda's Latest Approval in China Boosts Merck
September 11, 2021
From Motley Fool
Why This Citius Analyst Thinks The Biopharma's Shares Present 375% Upside Potential
September 10, 2021
From Benzinga
Merck Investors Have Reason to Cheer This Label Expansion
September 09, 2021
From Motley Fool
Dr Reddy's To Sell Its Anti-Cancer Agent To Citius Pharma
September 07, 2021
From Benzinga
From Benzinga
From Benzinga
The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In a Light Week
August 29, 2021
From Benzinga
What This Label Expansion Means for Merck
August 22, 2021
From Motley Fool
White House Dismisses Janet Woodcock As Permanent FDA Commissioner Candidate: Bloomberg
August 20, 2021
From Benzinga
From Benzinga
The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
August 15, 2021
From Benzinga
From Benzinga
Biogen's New Alzheimer's Drug Turned Away By Veterans Affairs
August 12, 2021
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.